British Society of Gastroenterology statement on the proposed removal of prescriptions for GFD
Friday, 23 September 2016 09:36
The proposed removal by CCGs of prescriptions for Gluten Free Diets (GFD) is an important issue for the British Society of Gastroenterology (BSG) as it poses a direct impact on the care of patients with coeliac disease, as well as wider cost implications for the health economy.
The BSG's membership includes most of the consultants and specialists in gastroenterology in the UK that treat patients with coeliac disease and we would like to put on record our support for Coeliac UK on this issue. Adherence to the gluten-free diet remains the complete medical treatment and having coeliac disease therefore requires significant dietary modification. The use of gluten-free substitute staple foods facilitates the necessary dietary adaptation. Rates for adherence to the gluten-free diet can vary between 42-91%  and gluten-free staples on prescription have been related to adherence .
BSG Statement on the findings of the IBD Audit Report
Commenting, Dr Barney Hawthorne, Chairman of the IBD Section at the BSG, said:
"The British Society of Gastroenterology (BSG) welcomes the findings of the latest round of the UK IBD Audit published today by the Royal College of Physicians, particularly noting the data on the use of biosimilar versions of infliximab in the NHS, and welcomes the contribution of BSG members to the findings.
"In February this year the BSG has published a guidance document supporting their use in IBD patient care. The guidance advocates their use when prescribed by brand name, and emphasises the importance of ongoing pharmacovigilance for patients receiving these drugs through ongoing data collection through the UK IBD Registry.
"With the NHS facing significant increasing financial pressures, biosimilars contribute towards improving IBD patient care and outcome while creating efficiency savings of up to £3million annually in this therapeutic area alone. We are encouraged by the reports key findings, including biosimilar versions of infliximab being shown to be as effective as other originator versions. It is vital that the reductions in costs to the NHS are used to reinvest in improvements to IBD services.
"The BSG have worked hard with partners to develop a wider IBD programme in the UK – encompassing the IBD Audit, BSG’s IBD Registry and IBD Standards – and hope that this collaboration will continue to benefit patients with IBD."
Commissioning: Action Plan Report published
Monday, 05 September 2016 13:28
Further to the series of commissioning workshops the BSG ran in Birmingham, Newmarket, Manchester and London in May, please follow the link below to the final feedback Action Plan Report 'Achieving a Winning Business Case to Improve Outcomes in Gastroenterology & Hepatology Services'.
Those who also attended our Satellite Symposium on Thursday 23rd June at the BSG Annual Conference will know this Action Plan contains 'Ten Top Tips for Success' on the first page of the Report and in Appendix 1, Page 11 a 'Business Case Check List'. Appendix 2 on Pages 12 - 16 has two very useful Business Case Examples.
- Download full report [ 1.5 MB ]
UK National Screening Committee (UK NSC)
Friday, 02 September 2016 09:21
Stakeholder Conference 2016
Following the success of last year's inaugural event, this year's conference will be in London on Wednesday 14 December. As well as highlighting recent work of the UK NSC it will also mark the 20th anniversary since the committee was formed.
Confirmed speakers include:
- Sir Muir Gray, the UK NSC's first Programme Director
- Dr Angela Raffle, co-author of "Screening: Evidence and Practice"
- Prof Bob Steele, new Chair of the UK NSC
- Dr Anne Mackie, PHE Screening Director
Page 5 of 12